SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation
In this medfyle
National Kidney Foundation outline current knowledge and gaps in T2D.
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
Expert commentary
About this Medfyle
This Medfyle is provided as a service to healthcare professionals. It has been created from content originally published in Diabetes®, an official journal of the American Diabetes Association®, and is published in coordination with Sheridan. This MedFyle was created by GlobalPort (International) Limited with permission from the American Diabetes Association; neither Sheridan nor the American Diabetes Association takes any responsibility for its accuracy or for the use of any content therein by those reading or downloading such content.
The summary content was prepared by Marie Farrow for Medfyle, reviewed & approved by Kendra Vehik, PhD, MPH, University of South Florida, Tampa, FL, USA.
Original article:
Tuttle KR, Brosius FC 3rd, Cavender MA, Fioretto P, Fowler KJ, Heerspink HJL, Manley T, McGuire DK, Molitch ME, Mottl AK, Perreault L, Rosas SE, Rossing P, Sola L, Vallon V, Wanner C, Perkovic V. SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation. Diabetes. 2021 Jan;70(1):1-16. doi: 10.2337/dbi20-0040. Epub 2020 Oct 26. PMID: 33106255; PMCID: PMC8162454.
The authors of the original article had no part in the creation of the summary.
All Medfyle content, summaries, expert commentaries and slides are owned by GlobalPort (International) Limited. The original journal articles are an exclusive copyright of the American Diabetes Association.
This activity is supported by an educational grant from Lilly.
